HALEON US HOLDINGS LLC

HCR · Health Issues

Issues related to healthcare and payment for over-the-counter drugs; General education of over-the-counter switches, including reauthorization of the Over-the-Counter Monograph Drug User Fee Act and policies impacting a Nonprescription Drug Product with an Additional Condition for Nonprescription Use; H.R.4273/S.2292, Over-the-Counter Monograph Drug User Fee Amendments; FY2026 Continuing Appropriations and Extensions Act (H.R.5371/P.L.119-37).

Literal federal measure citations: H.R.4273, S.2292, H.R.5371

TAX · Taxation/Internal Revenue Code

Issues related to coverage of over-the-counter products with FSAs and HSAs.

BUD · Budget/Appropriations

Policies impacting access to over-the-counter products; FY2026 Financial Services and General Government Appropriations Act process (H.R.5166/S.3290).

Literal federal measure citations: H.R.5166, S.3290

TRD · Trade (domestic/foreign)

Policies impacting the supply chain and manufacturing of over-the-counter pharmaceutical products including tariffs.